Miridesap (BioDeep_00000837666)

   


代谢物信息卡片


Miridesap

化学式: C16H24N2O6 (340.1634284)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1CC(N(C1)C(=O)CCCCC(=O)N2CCCC2C(=O)O)C(=O)O
InChI: InChI=1S/C16H24N2O6/c19-13(17-9-3-5-11(17)15(21)22)7-1-2-8-14(20)18-10-4-6-12(18)16(23)24/h11-12H,1-10H2,(H,21,22)(H,23,24)/t11-,12-/m1/s1

描述信息

C78275 - Agent Affecting Blood or Body Fluid

同义名列表

1 个代谢物同义名

Miridesap



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Duncan Richards, Helen Millns, Louise Cookson, Mary Ann Lukas. An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study. Orphanet journal of rare diseases. 2022 07; 17(1):259. doi: 10.1186/s13023-022-02405-7. [PMID: 35810311]
  • Ashutosh Wechalekar, Gunnar Antoni, Wasfi Al Azzam, Mats Bergström, Swethajit Biswas, Chao Chen, Joseph Cheriyan, Matthew Cleveland, Louise Cookson, Paul Galette, Robert L Janiczek, Raymond Y Kwong, Mary Ann Lukas, Helen Millns, Duncan Richards, Ian Schneider, Scott D Solomon, Jens Sörensen, James Storey, Douglas Thompson, Guus van Dongen, Danielle J Vugts, Anders Wall, Gerhard Wikström, Rodney H Falk. Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study. BMC cardiovascular disorders. 2022 02; 22(1):49. doi: 10.1186/s12872-021-02407-6. [PMID: 35152886]
  • Duncan Richards, Mark Bamford, Lia Liefaard, Nazneen Haque, Gareth Lewis, Jim Storey, Disala Fernando, Subramanya Kumar, Douglas Thompson, Duncan S Holmes. Identification, preclinical profile, and clinical proof of concept of an orally bioavailable pro-drug of miridesap. British journal of pharmacology. 2020 04; 177(8):1853-1864. doi: 10.1111/bph.14956. [PMID: 31877231]
  • Hiroko Ino, Yohei Doi, Lia Liefaard, Louise Cookson, Chao Chen, Hiroshi Itoh, Harue Igarashi, Atsushi Nakano. Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Dose of Miridesap in Healthy Japanese Subjects. Clinical pharmacology in drug development. 2019 07; 8(5):612-618. doi: 10.1002/cpdd.631. [PMID: 30556959]
  • Simon E Kolstoe, Michelle C Jenvey, Alan Purvis, Mark E Light, Darren Thompson, Peter Hughes, Mark B Pepys, Stephen P Wood. Interaction of serum amyloid P component with hexanoyl bis(D-proline) (CPHPC). Acta crystallographica. Section D, Biological crystallography. 2014 Aug; 70(Pt 8):2232-40. doi: 10.1107/s1399004714013455. [PMID: 25084341]
  • Michael Rosenzweig, Heather Landau. Light chain (AL) amyloidosis: update on diagnosis and management. Journal of hematology & oncology. 2011 Nov; 4(?):47. doi: 10.1186/1756-8722-4-47. [PMID: 22100031]
  • David J Millar, Winston L Hutchinson, Mark B Pepys. Immunoradiometric assay for human serum amyloid P component. Journal of immunological methods. 2011 Aug; 371(1-2):18-24. doi: 10.1016/j.jim.2011.06.010. [PMID: 21708157]
  • Karl Bodin, Stephan Ellmerich, Melvyn C Kahan, Glenys A Tennent, Andrzej Loesch, Janet A Gilbertson, Winston L Hutchinson, Palma P Mangione, J Ruth Gallimore, David J Millar, Shane Minogue, Amar P Dhillon, Graham W Taylor, Arthur R Bradwell, Aviva Petrie, Julian D Gillmore, Vittorio Bellotti, Marina Botto, Philip N Hawkins, Mark B Pepys. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature. 2010 Nov; 468(7320):93-7. doi: 10.1038/nature09494. [PMID: 20962779]
  • Julian D Gillmore, Glenys A Tennent, Winston L Hutchinson, Janet Ruth Gallimore, Helen J Lachmann, Hugh J B Goodman, Mark Offer, David J Millar, Aviva Petrie, Philip N Hawkins, Mark B Pepys. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. British journal of haematology. 2010 Mar; 148(5):760-7. doi: 10.1111/j.1365-2141.2009.08036.x. [PMID: 20064157]
  • Simon E Kolstoe, Basil H Ridha, Vittorio Bellotti, Nan Wang, Carol V Robinson, Sebastian J Crutch, Geoffrey Keir, Riitta Kukkastenvehmas, J Ruth Gallimore, Winston L Hutchinson, Philip N Hawkins, Stephen P Wood, Martin N Rossor, Mark B Pepys. Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. Proceedings of the National Academy of Sciences of the United States of America. 2009 May; 106(18):7619-23. doi: 10.1073/pnas.0902640106. [PMID: 19372378]
  • M B Pepys, J Herbert, W L Hutchinson, G A Tennent, H J Lachmann, J R Gallimore, L B Lovat, T Bartfai, A Alanine, C Hertel, T Hoffmann, R Jakob-Roetne, R D Norcross, J A Kemp, K Yamamura, M Suzuki, G W Taylor, S Murray, D Thompson, A Purvis, S Kolstoe, S P Wood, P N Hawkins. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature. 2002 May; 417(6886):254-9. doi: 10.1038/417254a. [PMID: 12015594]